Targeting of Liver Mannan-Binding Lectin-Associated Serine Protease-3 with RNA Interference Ameliorates Disease in a Mouse Model of Rheumatoid Arthritis

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Targeting of Liver Mannan-Binding Lectin-Associated Serine Protease-3 with RNA Interference Ameliorates Disease in a Mouse Model of Rheumatoid Arthritis. / Banda, Nirmal K; Desai, Dhruv; Scheinman, Robert I; Pihl, Rasmus; Sekine, Hideharu; Fujita, Teizo; Sharma, Vibha; Hansen, Annette G; Garred, Peter; Thiel, Steffen; Borodovsky, Anna; Holers, V Michael.

In: ImmunoHorizons, Vol. 2, No. 8, 2018, p. 274-295.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Banda, NK, Desai, D, Scheinman, RI, Pihl, R, Sekine, H, Fujita, T, Sharma, V, Hansen, AG, Garred, P, Thiel, S, Borodovsky, A & Holers, VM 2018, 'Targeting of Liver Mannan-Binding Lectin-Associated Serine Protease-3 with RNA Interference Ameliorates Disease in a Mouse Model of Rheumatoid Arthritis', ImmunoHorizons, vol. 2, no. 8, pp. 274-295. https://doi.org/10.4049/immunohorizons.1800053

APA

Banda, N. K., Desai, D., Scheinman, R. I., Pihl, R., Sekine, H., Fujita, T., Sharma, V., Hansen, A. G., Garred, P., Thiel, S., Borodovsky, A., & Holers, V. M. (2018). Targeting of Liver Mannan-Binding Lectin-Associated Serine Protease-3 with RNA Interference Ameliorates Disease in a Mouse Model of Rheumatoid Arthritis. ImmunoHorizons, 2(8), 274-295. https://doi.org/10.4049/immunohorizons.1800053

Vancouver

Banda NK, Desai D, Scheinman RI, Pihl R, Sekine H, Fujita T et al. Targeting of Liver Mannan-Binding Lectin-Associated Serine Protease-3 with RNA Interference Ameliorates Disease in a Mouse Model of Rheumatoid Arthritis. ImmunoHorizons. 2018;2(8):274-295. https://doi.org/10.4049/immunohorizons.1800053

Author

Banda, Nirmal K ; Desai, Dhruv ; Scheinman, Robert I ; Pihl, Rasmus ; Sekine, Hideharu ; Fujita, Teizo ; Sharma, Vibha ; Hansen, Annette G ; Garred, Peter ; Thiel, Steffen ; Borodovsky, Anna ; Holers, V Michael. / Targeting of Liver Mannan-Binding Lectin-Associated Serine Protease-3 with RNA Interference Ameliorates Disease in a Mouse Model of Rheumatoid Arthritis. In: ImmunoHorizons. 2018 ; Vol. 2, No. 8. pp. 274-295.

Bibtex

@article{05e36c9bc3e04b69afb267f295a733a5,
title = "Targeting of Liver Mannan-Binding Lectin-Associated Serine Protease-3 with RNA Interference Ameliorates Disease in a Mouse Model of Rheumatoid Arthritis",
abstract = "Mannan-binding lectin-associated serine protease 3 (MASP-3) regulates the alternative pathway of complement and is predominantly synthesized in the liver. The role of liver-derived MASP-3 in the pathogenesis of rheumatoid arthritis (RA) is unknown. We hypothesized that liver-derived MASP-3 is essential for the development of joint damage and that targeted inhibition of MASP-3 in the liver can attenuate arthritis. We used MASP-3-specific small interfering RNAs (siRNAs) conjugated to N-acetylgalactosamine (GalNAc) to specifically target the liver via asialoglycoprotein receptors. Active GalNAc-MASP3-siRNA conjugates were identified, and in vivo silencing of liver MASP-3 mRNA was demonstrated in healthy mice. The s.c. treatment with GalNAc-MASP-3-siRNAs specifically decreased the expression of MASP-3 in the liver and the level of MASP-3 protein in circulation of mice without affecting the levels of the other spliced products. In mice with collagen Ab-induced arthritis, s.c. administration of GalNAc-MASP-3-siRNA decreased the clinical disease activity score to 50% of controls, with decrease in histopathology scores and MASP-3 deposition. To confirm the ability to perform MASP-3 gene silencing in human cells, we generated a lentivirus expressing a short hairpin RNA specific for human MASP-3 mRNA. This procedure not only eliminated the short-term (at day 15) expression of MASP-3 in HepG2 and T98G cell lines but also diminished the long-term (at day 60) synthesis of MASP-3 protein in T98G cells. Our study demonstrates that isoform-specific silencing of MASP-3 in vivo modifies disease activity in a mouse model of RA and suggests that liver-directed MASP3 silencing may be a therapeutic approach in human RA.",
author = "Banda, {Nirmal K} and Dhruv Desai and Scheinman, {Robert I} and Rasmus Pihl and Hideharu Sekine and Teizo Fujita and Vibha Sharma and Hansen, {Annette G} and Peter Garred and Steffen Thiel and Anna Borodovsky and Holers, {V Michael}",
year = "2018",
doi = "10.4049/immunohorizons.1800053",
language = "English",
volume = "2",
pages = "274--295",
journal = "ImmunoHorizons",
issn = "2573-7732",
publisher = "American Association of Immunologists",
number = "8",

}

RIS

TY - JOUR

T1 - Targeting of Liver Mannan-Binding Lectin-Associated Serine Protease-3 with RNA Interference Ameliorates Disease in a Mouse Model of Rheumatoid Arthritis

AU - Banda, Nirmal K

AU - Desai, Dhruv

AU - Scheinman, Robert I

AU - Pihl, Rasmus

AU - Sekine, Hideharu

AU - Fujita, Teizo

AU - Sharma, Vibha

AU - Hansen, Annette G

AU - Garred, Peter

AU - Thiel, Steffen

AU - Borodovsky, Anna

AU - Holers, V Michael

PY - 2018

Y1 - 2018

N2 - Mannan-binding lectin-associated serine protease 3 (MASP-3) regulates the alternative pathway of complement and is predominantly synthesized in the liver. The role of liver-derived MASP-3 in the pathogenesis of rheumatoid arthritis (RA) is unknown. We hypothesized that liver-derived MASP-3 is essential for the development of joint damage and that targeted inhibition of MASP-3 in the liver can attenuate arthritis. We used MASP-3-specific small interfering RNAs (siRNAs) conjugated to N-acetylgalactosamine (GalNAc) to specifically target the liver via asialoglycoprotein receptors. Active GalNAc-MASP3-siRNA conjugates were identified, and in vivo silencing of liver MASP-3 mRNA was demonstrated in healthy mice. The s.c. treatment with GalNAc-MASP-3-siRNAs specifically decreased the expression of MASP-3 in the liver and the level of MASP-3 protein in circulation of mice without affecting the levels of the other spliced products. In mice with collagen Ab-induced arthritis, s.c. administration of GalNAc-MASP-3-siRNA decreased the clinical disease activity score to 50% of controls, with decrease in histopathology scores and MASP-3 deposition. To confirm the ability to perform MASP-3 gene silencing in human cells, we generated a lentivirus expressing a short hairpin RNA specific for human MASP-3 mRNA. This procedure not only eliminated the short-term (at day 15) expression of MASP-3 in HepG2 and T98G cell lines but also diminished the long-term (at day 60) synthesis of MASP-3 protein in T98G cells. Our study demonstrates that isoform-specific silencing of MASP-3 in vivo modifies disease activity in a mouse model of RA and suggests that liver-directed MASP3 silencing may be a therapeutic approach in human RA.

AB - Mannan-binding lectin-associated serine protease 3 (MASP-3) regulates the alternative pathway of complement and is predominantly synthesized in the liver. The role of liver-derived MASP-3 in the pathogenesis of rheumatoid arthritis (RA) is unknown. We hypothesized that liver-derived MASP-3 is essential for the development of joint damage and that targeted inhibition of MASP-3 in the liver can attenuate arthritis. We used MASP-3-specific small interfering RNAs (siRNAs) conjugated to N-acetylgalactosamine (GalNAc) to specifically target the liver via asialoglycoprotein receptors. Active GalNAc-MASP3-siRNA conjugates were identified, and in vivo silencing of liver MASP-3 mRNA was demonstrated in healthy mice. The s.c. treatment with GalNAc-MASP-3-siRNAs specifically decreased the expression of MASP-3 in the liver and the level of MASP-3 protein in circulation of mice without affecting the levels of the other spliced products. In mice with collagen Ab-induced arthritis, s.c. administration of GalNAc-MASP-3-siRNA decreased the clinical disease activity score to 50% of controls, with decrease in histopathology scores and MASP-3 deposition. To confirm the ability to perform MASP-3 gene silencing in human cells, we generated a lentivirus expressing a short hairpin RNA specific for human MASP-3 mRNA. This procedure not only eliminated the short-term (at day 15) expression of MASP-3 in HepG2 and T98G cell lines but also diminished the long-term (at day 60) synthesis of MASP-3 protein in T98G cells. Our study demonstrates that isoform-specific silencing of MASP-3 in vivo modifies disease activity in a mouse model of RA and suggests that liver-directed MASP3 silencing may be a therapeutic approach in human RA.

U2 - 10.4049/immunohorizons.1800053

DO - 10.4049/immunohorizons.1800053

M3 - Journal article

C2 - 30417171

VL - 2

SP - 274

EP - 295

JO - ImmunoHorizons

JF - ImmunoHorizons

SN - 2573-7732

IS - 8

ER -

ID: 218726013